David Shaw’s Medifast MED Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $980K | Sell |
92,345
-68,219
| -42% | -$787K | ﹤0.01% | 3762 |
|
|
2026
Q1 | $1.64M | Sell |
160,564
-58,554
| -27% | -$631K | ﹤0.01% | 3068 |
|
|
2025
Q4 | $2.34M | Sell |
219,118
-44,530
| -17% | -$533K | ﹤0.01% | 2925 |
|
|
2025
Q3 | $3.6M | Sell |
263,648
-57,581
| -18% | -$804K | ﹤0.01% | 2502 |
|
|
2025
Q2 | $4.51M | Sell |
321,229
-12,217
| -4% | -$161K | ﹤0.01% | 2109 |
|
|
2025
Q1 | $4.49M | Buy |
333,446
+44,663
| +15% | +$671K | ﹤0.01% | 1977 |
|
|
2024
Q4 | $5.09M | Buy |
288,783
+80,000
| +38% | +$1.48M | ﹤0.01% | 1966 |
|
|
2024
Q3 | $4M | Sell |
208,783
-129,025
| -38% | -$2.49M | ﹤0.01% | 2121 |
|
|
2024
Q2 | $7.37M | Buy |
337,808
+245,923
| +268% | +$6.56M | 0.01% | 1554 |
|
|
2024
Q1 | $3.52M | Buy |
91,885
+40,647
| +79% | +$1.97M | ﹤0.01% | 2178 |
|
|
2023
Q4 | $3.44M | Buy |
51,238
+389
| +0.8% | +$27.1K | ﹤0.01% | 2226 |
|
|
2023
Q3 | $3.81M | Sell |
50,849
-28,792
| -36% | -$2.55M | ﹤0.01% | 2061 |
|
|
2023
Q2 | $7.34M | Sell |
79,641
-6,530
| -8% | -$581K | 0.01% | 1591 |
|
|
2023
Q1 | $8.93M | Buy |
86,171
+70,108
| +436% | +$7.77M | 0.01% | 1463 |
|
|
2022
Q4 | $1.85M | Buy |
16,063
+13,160
| +453% | +$1.53M | ﹤0.01% | 2994 |
|
|
2022
Q3 | $315K | Buy |
2,903
+1,679
| +137% | +$241K | ﹤0.01% | 4274 |
|
|
2022
Q2 | $221K | Sell |
1,224
-757
| -38% | -$135K | ﹤0.01% | 4505 |
|
|
2022
Q1 | $338K | Sell |
1,981
-9,493
| -83% | -$1.79M | ﹤0.01% | 4591 |
|
|
2021
Q4 | $2.4M | Buy |
+11,474
| New | +$2.37M | ﹤0.01% | 3190 |
|
|
2021
Q2 | – | Sell |
-2,397
| Closed | -$650K | – | 4904 |
|
|
2021
Q1 | $508K | Buy |
+2,397
| New | +$574K | ﹤0.01% | 3492 |
|
|
2020
Q2 | – | Sell |
-4,707
| Closed | -$432K | – | 4155 |
|
|
2020
Q1 | $294K | Buy |
+4,707
| New | +$429K | ﹤0.01% | 3481 |
|
|
2018
Q4 | – | Sell |
-1,031
| Closed | -$176K | – | 3903 |
|
|
2018
Q3 | $228K | Sell |
1,031
-12,523
| -92% | -$2.54M | ﹤0.01% | 3490 |
|
|
2018
Q2 | $2.17M | Sell |
13,554
-3,268
| -19% | -$418K | ﹤0.01% | 2167 |
|
|
2018
Q1 | $1.57M | Sell |
16,822
-28,985
| -63% | -$2.17M | ﹤0.01% | 2205 |
|
|
2017
Q4 | $3.2M | Sell |
45,807
-11,562
| -20% | -$767K | ﹤0.01% | 1800 |
|
|
2017
Q3 | $3.41M | Buy |
57,369
+4,656
| +9% | +$232K | 0.01% | 1665 |
|
|
2017
Q2 | $2.19M | Buy |
52,713
+17,944
| +52% | +$780K | ﹤0.01% | 1918 |
|
|
2017
Q1 | $1.54M | Buy |
34,769
+5,526
| +19% | +$238K | ﹤0.01% | 2021 |
|
|
2016
Q4 | $1.22M | Sell |
29,243
-39,548
| -57% | -$1.59M | ﹤0.01% | 2341 |
|
|
2016
Q3 | $2.6M | Sell |
68,791
-36,033
| -34% | -$1.29M | ﹤0.01% | 1722 |
|
|
2016
Q2 | $3.49M | Buy |
104,824
+37,968
| +57% | +$1.23M | 0.01% | 1523 |
|
|
2016
Q1 | $2.02M | Sell |
66,856
-15,591
| -19% | -$456K | ﹤0.01% | 1873 |
|
|
2015
Q4 | $2.5M | Buy |
82,447
+26,601
| +48% | +$792K | ﹤0.01% | 1955 |
|
|
2015
Q3 | $1.5M | Buy |
55,846
+14,823
| +36% | +$432K | ﹤0.01% | 2309 |
|
|
2015
Q2 | $1.33M | Buy |
+41,023
| New | +$1.3M | ﹤0.01% | 2497 |
|
|
2014
Q3 | – | Sell |
-16,872
| Closed | -$518K | – | 4272 |
|
|
2014
Q2 | $513K | Sell |
16,872
-20,503
| -55% | -$639K | ﹤0.01% | 3508 |
|
|
2014
Q1 | $1.09M | Buy |
+37,375
| New | +$1M | ﹤0.01% | 2951 |
|
Other funds holding MED
SCP
David Shaw's MED Position: Q2 2026 in Review
David Shaw reduced its Medifast (MED) stake by 42% in Q2 2026, selling an estimated $787K and leaving 92,345 shares worth $980K. The position accounts for ﹤0.01% of the portfolio, ranked #3762.
David Shaw first reported a position in MED in Q1 2014 and has held it in 37 quarters since. The position peaked at $8.93M in Q1 2023. 112 funds tracked by Wall St. Rank hold MED as of Q2 2026.
- David Shaw held 92,345 shares of Medifast worth $980K as of Q2 2026.
- David Shaw sold 68,219 Medifast shares in Q2 2026, an estimated $787K.
- Medifast made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #3762 holding.
- David Shaw first reported a position in Medifast in Q1 2014 and has held it in 37 quarters since.
- David Shaw's Medifast position peaked at $8.93M in Q1 2023.
- 112 funds tracked by Wall St. Rank held Medifast as of Q2 2026.
Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.